Share Price and Basic Stock Data
Last Updated: November 20, 2025, 7:59 pm
| PEG Ratio | -37.20 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Neogen Chemicals Ltd operates in the specialty chemicals sector, with a current market capitalization of ₹3,422 Cr. The company’s stock price stands at ₹1,298, reflecting a price-to-earnings ratio (P/E) of 69.3, indicating a premium valuation in comparison to typical industry benchmarks. Over the last fiscal years, Neogen reported a notable rise in sales from ₹336 Cr in FY 2021 to ₹686 Cr in FY 2023, with a trailing twelve months (TTM) revenue of ₹795 Cr. The revenue growth trajectory appears to be sustained, as evidenced by quarterly sales figures that increased from ₹148 Cr in June 2022 to ₹204 Cr in March 2025. However, the sales dipped slightly to ₹170 Cr in June 2023 and ₹168 Cr in September 2023, suggesting potential volatility in demand. The operating profit margin (OPM) fluctuated, with the most recent reported figure of 19% in the latest quarter, underscoring the challenges of maintaining profitability amidst rising operational costs.
Profitability and Efficiency Metrics
Neogen’s profitability metrics reflect a mixed performance, with net profit recorded at ₹43 Cr and a return on equity (ROE) of 7.36%, which is relatively low for the sector. The operating profit for FY 2023 was ₹112 Cr, translating to an OPM of 16%, down from previous highs, indicating pressure on margins. The interest coverage ratio (ICR) stood at 2.89x, suggesting adequate ability to service debt, although this is lower than the ideal benchmark of 3x. The cash conversion cycle (CCC) of 138 days reveals inefficiencies in working capital management, particularly when juxtaposed against typical industry standards. Moreover, the company’s return on capital employed (ROCE) was reported at 10.7%, indicating room for improvement in capital utilization. These profitability and efficiency metrics highlight both the challenges Neogen faces in maintaining margins and the potential for operational enhancements.
Balance Sheet Strength and Financial Ratios
As of the latest reporting period, Neogen Chemicals maintains a robust balance sheet, with total assets valued at ₹1,621 Cr and total borrowings of ₹474 Cr, resulting in a debt-to-equity ratio of 0.71x. This indicates a manageable level of debt relative to equity, although industry norms typically favor lower ratios. The company’s reserves have increased to ₹782 Cr, reflecting prudent financial management in retaining earnings. Additionally, the price-to-book value (P/BV) ratio stood at 5.16x, suggesting that the market has a high valuation relative to the book value, which may indicate investor confidence or overvaluation. The current ratio of 1.36x suggests that Neogen possesses sufficient liquidity to meet short-term obligations, while the quick ratio of 0.94x indicates potential liquidity constraints. These financial ratios demonstrate a balanced approach to growth and risk management, although there are areas that warrant close monitoring.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Neogen Chemicals reveals a diverse ownership structure, with promoters holding 51.22% of the equity, reflecting a controlling interest. Foreign institutional investors (FIIs) have a stake of 5.15%, while domestic institutional investors (DIIs) hold 25.22%, indicating a strong institutional backing. The public shareholding stands at 18.40%, with the number of shareholders recorded at 45,710. The gradual decline in promoter holding from 60.19% in December 2022 to the current level may raise questions about management’s commitment to the company’s long-term growth. Nonetheless, the increase in DII holdings from 18.89% in December 2022 to 25.22% by March 2025 suggests growing confidence among domestic institutions in Neogen’s future prospects. This diversified shareholding can enhance stability and support for the company’s strategic initiatives.
Outlook, Risks, and Final Insight
Neogen Chemicals faces a landscape of both opportunities and challenges. On the upside, the increasing demand for specialty chemicals driven by various end-user industries presents growth potential. However, the company must navigate risks such as margin pressures due to rising raw material costs and potential volatility in sales, as evidenced by recent quarterly fluctuations. Additionally, the elevated P/E ratio may indicate that the stock is overvalued, which could deter new investors if market conditions shift. The need for operational efficiency improvements is critical, particularly in light of the extended cash conversion cycle. Overall, Neogen’s strategic focus on enhancing profitability and managing debt levels will be essential in sustaining long-term growth and shareholder value, particularly as it adapts to an evolving market environment.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Neogen Chemicals Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| HP Adhesives Ltd | 430 Cr. | 47.0 | 86.7/42.6 | 26.7 | 20.5 | 0.85 % | 13.6 % | 9.82 % | 2.00 |
| Haryana Leather Chemicals Ltd | 35.8 Cr. | 73.0 | 103/56.0 | 17.2 | 89.6 | 1.37 % | 8.02 % | 5.45 % | 10.0 |
| Hardcastle & Waud Mfg Co Ltd | 44.9 Cr. | 661 | 988/600 | 20.7 | 697 | 0.00 % | 6.31 % | 2.91 % | 10.0 |
| Grauer & Weil (India) Ltd | 3,717 Cr. | 82.0 | 111/78.0 | 24.6 | 22.0 | 0.61 % | 23.3 % | 17.6 % | 1.00 |
| DMCC Speciality Chemicals Ltd | 663 Cr. | 266 | 453/241 | 23.8 | 93.8 | 0.94 % | 14.1 % | 9.97 % | 10.0 |
| Industry Average | 12,962.80 Cr | 744.41 | 64.06 | 182.93 | 0.42% | 12.99% | 25.41% | 6.41 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 148 | 148 | 186 | 204 | 170 | 168 | 164 | 210 | 176 | 193 | 200 | 204 | 185 |
| Expenses | 123 | 124 | 156 | 171 | 141 | 142 | 143 | 172 | 145 | 157 | 163 | 163 | 150 |
| Operating Profit | 25 | 24 | 30 | 33 | 29 | 26 | 22 | 38 | 32 | 36 | 38 | 41 | 35 |
| OPM % | 17% | 16% | 16% | 16% | 17% | 16% | 13% | 18% | 18% | 19% | 19% | 20% | 19% |
| Other Income | 1 | 0 | 1 | 2 | 2 | 2 | 2 | 3 | 3 | 2 | 2 | -11 | 3 |
| Interest | 6 | 7 | 7 | 9 | 11 | 11 | 11 | 10 | 10 | 12 | 13 | 16 | 14 |
| Depreciation | 4 | 4 | 4 | 4 | 5 | 5 | 6 | 6 | 6 | 7 | 7 | 6 | 5 |
| Profit before tax | 16 | 14 | 21 | 21 | 16 | 12 | 7 | 25 | 19 | 20 | 20 | 8 | 19 |
| Tax % | 29% | 29% | 29% | 31% | 28% | 26% | 69% | 24% | 26% | 25% | 28% | 33% | 25% |
| Net Profit | 11 | 10 | 15 | 14 | 11 | 9 | 2 | 19 | 14 | 15 | 14 | 5 | 14 |
| EPS in Rs | 4.46 | 3.97 | 5.90 | 5.75 | 4.58 | 3.66 | 0.85 | 7.30 | 5.28 | 5.63 | 5.46 | 1.97 | 5.39 |
Last Updated: August 20, 2025, 6:15 am
Below is a detailed analysis of the quarterly data for Neogen Chemicals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 185.00 Cr.. The value appears to be declining and may need further review. It has decreased from 204.00 Cr. (Mar 2025) to 185.00 Cr., marking a decrease of 19.00 Cr..
- For Expenses, as of Jun 2025, the value is 150.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 163.00 Cr. (Mar 2025) to 150.00 Cr., marking a decrease of 13.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 35.00 Cr.. The value appears to be declining and may need further review. It has decreased from 41.00 Cr. (Mar 2025) to 35.00 Cr., marking a decrease of 6.00 Cr..
- For OPM %, as of Jun 2025, the value is 19.00%. The value appears to be declining and may need further review. It has decreased from 20.00% (Mar 2025) to 19.00%, marking a decrease of 1.00%.
- For Other Income, as of Jun 2025, the value is 3.00 Cr.. The value appears strong and on an upward trend. It has increased from -11.00 Cr. (Mar 2025) to 3.00 Cr., marking an increase of 14.00 Cr..
- For Interest, as of Jun 2025, the value is 14.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 16.00 Cr. (Mar 2025) to 14.00 Cr., marking a decrease of 2.00 Cr..
- For Depreciation, as of Jun 2025, the value is 5.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 6.00 Cr. (Mar 2025) to 5.00 Cr., marking a decrease of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 19.00 Cr.. The value appears strong and on an upward trend. It has increased from 8.00 Cr. (Mar 2025) to 19.00 Cr., marking an increase of 11.00 Cr..
- For Tax %, as of Jun 2025, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 33.00% (Mar 2025) to 25.00%, marking a decrease of 8.00%.
- For Net Profit, as of Jun 2025, the value is 14.00 Cr.. The value appears strong and on an upward trend. It has increased from 5.00 Cr. (Mar 2025) to 14.00 Cr., marking an increase of 9.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 5.39. The value appears strong and on an upward trend. It has increased from 1.97 (Mar 2025) to 5.39, marking an increase of 3.42.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 4:47 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 74 | 84 | 100 | 110 | 161 | 239 | 306 | 336 | 487 | 686 | 701 | 774 | 795 |
| Expenses | 62 | 71 | 86 | 90 | 132 | 196 | 248 | 272 | 401 | 575 | 585 | 627 | 647 |
| Operating Profit | 11 | 13 | 14 | 20 | 29 | 43 | 58 | 64 | 87 | 112 | 116 | 147 | 148 |
| OPM % | 16% | 15% | 14% | 18% | 18% | 18% | 19% | 19% | 18% | 16% | 17% | 19% | 19% |
| Other Income | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 5 | 8 | -4 | -1 |
| Interest | 5 | 5 | 5 | 8 | 10 | 12 | 12 | 14 | 19 | 29 | 42 | 51 | 64 |
| Depreciation | 1 | 1 | 1 | 1 | 2 | 3 | 5 | 7 | 12 | 16 | 23 | 26 | 24 |
| Profit before tax | 6 | 8 | 8 | 12 | 18 | 29 | 41 | 44 | 57 | 71 | 59 | 66 | 59 |
| Tax % | 41% | 37% | 39% | 33% | 39% | 28% | 30% | 29% | 22% | 30% | 31% | 27% | |
| Net Profit | 4 | 5 | 5 | 8 | 11 | 21 | 29 | 31 | 45 | 50 | 41 | 48 | 43 |
| EPS in Rs | 8.09 | 11.31 | 2.59 | 3.88 | 5.34 | 10.48 | 12.33 | 13.47 | 17.93 | 20.07 | 15.59 | 18.35 | 16.35 |
| Dividend Payout % | 25% | 18% | 77% | 26% | 19% | 14% | 16% | 17% | 15% | 15% | 13% | 5% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 25.00% | 0.00% | 60.00% | 37.50% | 90.91% | 38.10% | 6.90% | 45.16% | 11.11% | -18.00% | 17.07% |
| Change in YoY Net Profit Growth (%) | 0.00% | -25.00% | 60.00% | -22.50% | 53.41% | -52.81% | -31.20% | 38.26% | -34.05% | -29.11% | 35.07% |
Neogen Chemicals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 25% |
| 5 Years: | 20% |
| 3 Years: | 17% |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 28% |
| 5 Years: | 15% |
| 3 Years: | 9% |
| TTM: | 23% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 16% |
| 3 Years: | -1% |
| 1 Year: | -1% |
| Return on Equity | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 10% |
| 3 Years: | 8% |
| Last Year: | 7% |
Last Updated: September 5, 2025, 11:40 am
Balance Sheet
Last Updated: October 10, 2025, 2:37 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 20 | 20 | 20 | 20 | 23 | 23 | 25 | 25 | 26 | 26 |
| Reserves | 15 | 19 | 8 | 22 | 31 | 50 | 133 | 160 | 414 | 458 | 740 | 782 |
| Borrowings | 25 | 24 | 26 | 69 | 82 | 120 | 137 | 222 | 229 | 370 | 409 | 474 |
| Other Liabilities | 18 | 21 | 27 | 41 | 48 | 56 | 61 | 87 | 131 | 202 | 230 | 338 |
| Total Liabilities | 63 | 69 | 80 | 152 | 181 | 247 | 355 | 492 | 800 | 1,054 | 1,405 | 1,621 |
| Fixed Assets | 14 | 13 | 17 | 56 | 67 | 83 | 111 | 127 | 285 | 347 | 361 | 228 |
| CWIP | 0 | 0 | 1 | 1 | 1 | 0 | 3 | 115 | 11 | 36 | 56 | 28 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 81 | 77 | 5 | 193 |
| Other Assets | 49 | 55 | 62 | 94 | 112 | 163 | 242 | 250 | 423 | 594 | 983 | 1,173 |
| Total Assets | 63 | 69 | 80 | 152 | 181 | 247 | 355 | 492 | 800 | 1,054 | 1,405 | 1,621 |
Below is a detailed analysis of the balance sheet data for Neogen Chemicals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 26.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 26.00 Cr..
- For Reserves, as of Mar 2025, the value is 782.00 Cr.. The value appears strong and on an upward trend. It has increased from 740.00 Cr. (Mar 2024) to 782.00 Cr., marking an increase of 42.00 Cr..
- For Borrowings, as of Mar 2025, the value is 474.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 409.00 Cr. (Mar 2024) to 474.00 Cr., marking an increase of 65.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 338.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 230.00 Cr. (Mar 2024) to 338.00 Cr., marking an increase of 108.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 1,621.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,405.00 Cr. (Mar 2024) to 1,621.00 Cr., marking an increase of 216.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 228.00 Cr.. The value appears to be declining and may need further review. It has decreased from 361.00 Cr. (Mar 2024) to 228.00 Cr., marking a decrease of 133.00 Cr..
- For CWIP, as of Mar 2025, the value is 28.00 Cr.. The value appears to be declining and may need further review. It has decreased from 56.00 Cr. (Mar 2024) to 28.00 Cr., marking a decrease of 28.00 Cr..
- For Investments, as of Mar 2025, the value is 193.00 Cr.. The value appears strong and on an upward trend. It has increased from 5.00 Cr. (Mar 2024) to 193.00 Cr., marking an increase of 188.00 Cr..
- For Other Assets, as of Mar 2025, the value is 1,173.00 Cr.. The value appears strong and on an upward trend. It has increased from 983.00 Cr. (Mar 2024) to 1,173.00 Cr., marking an increase of 190.00 Cr..
- For Total Assets, as of Mar 2025, the value is 1,621.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,405.00 Cr. (Mar 2024) to 1,621.00 Cr., marking an increase of 216.00 Cr..
Notably, the Reserves (782.00 Cr.) exceed the Borrowings (474.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -14.00 | -11.00 | -12.00 | -49.00 | -53.00 | -77.00 | -79.00 | -158.00 | -142.00 | -258.00 | -293.00 | -327.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 82 | 78 | 58 | 107 | 94 | 93 | 90 | 85 | 82 | 94 | 147 | 94 |
| Inventory Days | 173 | 178 | 190 | 228 | 192 | 188 | 257 | 211 | 258 | 275 | 353 | 265 |
| Days Payable | 117 | 120 | 130 | 177 | 141 | 111 | 71 | 122 | 131 | 147 | 134 | 220 |
| Cash Conversion Cycle | 138 | 136 | 117 | 158 | 145 | 169 | 276 | 174 | 209 | 223 | 366 | 138 |
| Working Capital Days | 140 | 140 | 126 | 67 | 49 | 63 | 96 | 67 | 111 | 80 | 190 | 169 |
| ROCE % | 26% | 27% | 26% | 23% | 23% | 26% | 22% | 17% | 14% | 13% | 10% | 11% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Axis Small Cap Fund | 1,217,809 | 1.03 | 183.91 | 1,217,809 | 2025-04-22 17:25:25 | 0% |
| SBI Large & Midcap Fund | 935,051 | 0.81 | 139.66 | 935,051 | 2025-04-22 15:56:55 | 0% |
| SBI Contra Fund | 808,141 | 0.64 | 120.83 | 808,141 | 2025-04-22 15:56:55 | 0% |
| Quant Small Cap Fund | 427,577 | 0.58 | 64.57 | 427,577 | 2025-04-22 17:25:25 | 0% |
| Sundaram Small Cap Fund | 265,529 | 1.39 | 40.1 | 265,529 | 2025-04-22 15:56:55 | 0% |
| Axis Flexi Cap Fund | 212,801 | 0.29 | 32.14 | 212,801 | 2025-04-22 15:56:55 | 0% |
| SBI Equity Savings Fund | 212,711 | 0.98 | 31.78 | 212,711 | 2025-04-22 17:25:25 | 0% |
| Tata ELSS Tax Saver Fund | 199,536 | 0.81 | 30.13 | 199,536 | 2025-04-22 15:56:55 | 0% |
| Axis Special Situations Fund | 160,897 | 1.97 | 24.3 | 160,897 | 2025-04-22 17:25:25 | 0% |
| Union Small Cap Fund | 158,292 | 1.91 | 23.91 | 158,292 | 2025-04-22 15:56:55 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 13.20 | 13.96 | 20.03 | 18.70 | 13.45 |
| Diluted EPS (Rs.) | 13.20 | 13.96 | 20.03 | 18.70 | 13.45 |
| Cash EPS (Rs.) | 23.66 | 22.11 | 26.49 | 22.58 | 16.38 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 299.24 | 288.21 | 193.47 | 176.12 | 78.43 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 299.24 | 288.21 | 193.47 | 176.12 | 78.43 |
| Revenue From Operations / Share (Rs.) | 294.75 | 261.82 | 275.13 | 195.37 | 144.17 |
| PBDIT / Share (Rs.) | 53.20 | 44.55 | 46.54 | 35.22 | 27.81 |
| PBIT / Share (Rs.) | 42.66 | 35.88 | 40.04 | 30.53 | 24.85 |
| PBT / Share (Rs.) | 18.94 | 19.93 | 28.44 | 22.88 | 18.95 |
| Net Profit / Share (Rs.) | 13.13 | 13.45 | 20.00 | 17.89 | 13.43 |
| NP After MI And SOA / Share (Rs.) | 13.20 | 13.51 | 20.04 | 17.89 | 13.43 |
| PBDIT Margin (%) | 18.04 | 17.01 | 16.91 | 18.02 | 19.28 |
| PBIT Margin (%) | 14.47 | 13.70 | 14.55 | 15.62 | 17.23 |
| PBT Margin (%) | 6.42 | 7.61 | 10.33 | 11.71 | 13.14 |
| Net Profit Margin (%) | 4.45 | 5.13 | 7.26 | 9.15 | 9.31 |
| NP After MI And SOA Margin (%) | 4.47 | 5.16 | 7.28 | 9.15 | 9.31 |
| Return on Networth / Equity (%) | 4.41 | 4.68 | 10.35 | 10.16 | 17.11 |
| Return on Capital Employeed (%) | 11.09 | 10.12 | 15.50 | 13.10 | 18.23 |
| Return On Assets (%) | 1.99 | 2.43 | 4.74 | 5.58 | 6.36 |
| Long Term Debt / Equity (X) | 0.21 | 0.16 | 0.26 | 0.27 | 0.63 |
| Total Debt / Equity (X) | 0.71 | 0.51 | 0.75 | 0.45 | 1.10 |
| Asset Turnover Ratio (%) | 0.48 | 0.54 | 0.74 | 0.75 | 0.79 |
| Current Ratio (X) | 1.36 | 1.49 | 1.60 | 2.26 | 1.38 |
| Quick Ratio (X) | 0.94 | 0.76 | 0.88 | 1.37 | 0.72 |
| Inventory Turnover Ratio (X) | 1.46 | 1.41 | 1.99 | 2.23 | 1.48 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 20.98 | 13.72 | 11.76 | 14.89 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 12.78 | 10.36 | 9.32 | 12.20 |
| Earning Retention Ratio (%) | 0.00 | 79.02 | 86.28 | 88.24 | 85.11 |
| Cash Earning Retention Ratio (%) | 0.00 | 87.22 | 89.64 | 90.68 | 87.80 |
| Interest Coverage Ratio (X) | 2.89 | 2.79 | 4.01 | 4.60 | 4.71 |
| Interest Coverage Ratio (Post Tax) (X) | 2.00 | 1.84 | 2.72 | 3.34 | 3.28 |
| Enterprise Value (Cr.) | 4637.05 | 3527.65 | 3541.31 | 4504.16 | 2217.48 |
| EV / Net Operating Revenue (X) | 5.96 | 5.11 | 5.16 | 9.24 | 6.59 |
| EV / EBITDA (X) | 33.04 | 30.02 | 30.51 | 51.28 | 34.18 |
| MarketCap / Net Operating Revenue (X) | 5.24 | 4.56 | 4.66 | 8.93 | 5.99 |
| Retention Ratios (%) | 0.00 | 79.01 | 86.27 | 88.23 | 85.10 |
| Price / BV (X) | 5.16 | 4.14 | 6.63 | 9.91 | 11.02 |
| Price / Net Operating Revenue (X) | 5.24 | 4.56 | 4.66 | 8.93 | 6.00 |
| EarningsYield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
After reviewing the key financial ratios for Neogen Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 13.20. This value is within the healthy range. It has decreased from 13.96 (Mar 24) to 13.20, marking a decrease of 0.76.
- For Diluted EPS (Rs.), as of Mar 25, the value is 13.20. This value is within the healthy range. It has decreased from 13.96 (Mar 24) to 13.20, marking a decrease of 0.76.
- For Cash EPS (Rs.), as of Mar 25, the value is 23.66. This value is within the healthy range. It has increased from 22.11 (Mar 24) to 23.66, marking an increase of 1.55.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 299.24. It has increased from 288.21 (Mar 24) to 299.24, marking an increase of 11.03.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 299.24. It has increased from 288.21 (Mar 24) to 299.24, marking an increase of 11.03.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 294.75. It has increased from 261.82 (Mar 24) to 294.75, marking an increase of 32.93.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 53.20. This value is within the healthy range. It has increased from 44.55 (Mar 24) to 53.20, marking an increase of 8.65.
- For PBIT / Share (Rs.), as of Mar 25, the value is 42.66. This value is within the healthy range. It has increased from 35.88 (Mar 24) to 42.66, marking an increase of 6.78.
- For PBT / Share (Rs.), as of Mar 25, the value is 18.94. This value is within the healthy range. It has decreased from 19.93 (Mar 24) to 18.94, marking a decrease of 0.99.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 13.13. This value is within the healthy range. It has decreased from 13.45 (Mar 24) to 13.13, marking a decrease of 0.32.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 13.20. This value is within the healthy range. It has decreased from 13.51 (Mar 24) to 13.20, marking a decrease of 0.31.
- For PBDIT Margin (%), as of Mar 25, the value is 18.04. This value is within the healthy range. It has increased from 17.01 (Mar 24) to 18.04, marking an increase of 1.03.
- For PBIT Margin (%), as of Mar 25, the value is 14.47. This value is within the healthy range. It has increased from 13.70 (Mar 24) to 14.47, marking an increase of 0.77.
- For PBT Margin (%), as of Mar 25, the value is 6.42. This value is below the healthy minimum of 10. It has decreased from 7.61 (Mar 24) to 6.42, marking a decrease of 1.19.
- For Net Profit Margin (%), as of Mar 25, the value is 4.45. This value is below the healthy minimum of 5. It has decreased from 5.13 (Mar 24) to 4.45, marking a decrease of 0.68.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 4.47. This value is below the healthy minimum of 8. It has decreased from 5.16 (Mar 24) to 4.47, marking a decrease of 0.69.
- For Return on Networth / Equity (%), as of Mar 25, the value is 4.41. This value is below the healthy minimum of 15. It has decreased from 4.68 (Mar 24) to 4.41, marking a decrease of 0.27.
- For Return on Capital Employeed (%), as of Mar 25, the value is 11.09. This value is within the healthy range. It has increased from 10.12 (Mar 24) to 11.09, marking an increase of 0.97.
- For Return On Assets (%), as of Mar 25, the value is 1.99. This value is below the healthy minimum of 5. It has decreased from 2.43 (Mar 24) to 1.99, marking a decrease of 0.44.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.21. This value is within the healthy range. It has increased from 0.16 (Mar 24) to 0.21, marking an increase of 0.05.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.71. This value is within the healthy range. It has increased from 0.51 (Mar 24) to 0.71, marking an increase of 0.20.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.48. It has decreased from 0.54 (Mar 24) to 0.48, marking a decrease of 0.06.
- For Current Ratio (X), as of Mar 25, the value is 1.36. This value is below the healthy minimum of 1.5. It has decreased from 1.49 (Mar 24) to 1.36, marking a decrease of 0.13.
- For Quick Ratio (X), as of Mar 25, the value is 0.94. This value is below the healthy minimum of 1. It has increased from 0.76 (Mar 24) to 0.94, marking an increase of 0.18.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.46. This value is below the healthy minimum of 4. It has increased from 1.41 (Mar 24) to 1.46, marking an increase of 0.05.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 20.98 (Mar 24) to 0.00, marking a decrease of 20.98.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 12.78 (Mar 24) to 0.00, marking a decrease of 12.78.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 79.02 (Mar 24) to 0.00, marking a decrease of 79.02.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 87.22 (Mar 24) to 0.00, marking a decrease of 87.22.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.89. This value is below the healthy minimum of 3. It has increased from 2.79 (Mar 24) to 2.89, marking an increase of 0.10.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.00. This value is below the healthy minimum of 3. It has increased from 1.84 (Mar 24) to 2.00, marking an increase of 0.16.
- For Enterprise Value (Cr.), as of Mar 25, the value is 4,637.05. It has increased from 3,527.65 (Mar 24) to 4,637.05, marking an increase of 1,109.40.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 5.96. This value exceeds the healthy maximum of 3. It has increased from 5.11 (Mar 24) to 5.96, marking an increase of 0.85.
- For EV / EBITDA (X), as of Mar 25, the value is 33.04. This value exceeds the healthy maximum of 15. It has increased from 30.02 (Mar 24) to 33.04, marking an increase of 3.02.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 5.24. This value exceeds the healthy maximum of 3. It has increased from 4.56 (Mar 24) to 5.24, marking an increase of 0.68.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 79.01 (Mar 24) to 0.00, marking a decrease of 79.01.
- For Price / BV (X), as of Mar 25, the value is 5.16. This value exceeds the healthy maximum of 3. It has increased from 4.14 (Mar 24) to 5.16, marking an increase of 1.02.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 5.24. This value exceeds the healthy maximum of 3. It has increased from 4.56 (Mar 24) to 5.24, marking an increase of 0.68.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Neogen Chemicals Ltd:
- Net Profit Margin: 4.45%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 11.09% (Industry Average ROCE: 12.99%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 4.41% (Industry Average ROE: 24.61%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.94
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 68 (Industry average Stock P/E: 56.05)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.71
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 4.45%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Speciality - Others | No. 1002, 10th Floor, Thane Maharashtra 400601 | investor@neogenchem.com http://www.neogenchem.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Haridas Kanani | Chairman & Managing Director |
| Dr. Harin Kanani | Managing Director |
| Mr. Shyamsunder Upadhyay | Whole Time Director |
| Mr. Anurag Surana | Non Exe.Non Ind.Director |
| Mr. Sanjay Mehta | Independent Director |
| Mr. Hitesh Reshamwala | Independent Director |
| Prof. Ranjan Kumar Malik | Independent Director |
| Mrs. Avi Sabavala | Independent Director |
FAQ
What is the intrinsic value of Neogen Chemicals Ltd?
Neogen Chemicals Ltd's intrinsic value (as of 21 November 2025) is 1258.21 which is 0.85% lower the current market price of 1,269.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 3,360 Cr. market cap, FY2025-2026 high/low of 2,420/1,196, reserves of ₹782 Cr, and liabilities of 1,621 Cr.
What is the Market Cap of Neogen Chemicals Ltd?
The Market Cap of Neogen Chemicals Ltd is 3,360 Cr..
What is the current Stock Price of Neogen Chemicals Ltd as on 21 November 2025?
The current stock price of Neogen Chemicals Ltd as on 21 November 2025 is 1,269.
What is the High / Low of Neogen Chemicals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Neogen Chemicals Ltd stocks is 2,420/1,196.
What is the Stock P/E of Neogen Chemicals Ltd?
The Stock P/E of Neogen Chemicals Ltd is 68.0.
What is the Book Value of Neogen Chemicals Ltd?
The Book Value of Neogen Chemicals Ltd is 314.
What is the Dividend Yield of Neogen Chemicals Ltd?
The Dividend Yield of Neogen Chemicals Ltd is 0.08 %.
What is the ROCE of Neogen Chemicals Ltd?
The ROCE of Neogen Chemicals Ltd is 10.7 %.
What is the ROE of Neogen Chemicals Ltd?
The ROE of Neogen Chemicals Ltd is 7.36 %.
What is the Face Value of Neogen Chemicals Ltd?
The Face Value of Neogen Chemicals Ltd is 10.0.